Skip to content
MarketScale
‹ Back to Industries

Sciences

Fifty Years Later, The Space Race is Back On

In the time since Neil Armstrong and Buzz Aldrin first landed on the moon on July 20, 1969, only 10 other men have walked on the lunar surface. Fifty years after this marvel of human achievement, there is a new desire to go back, not simply for exploration’s sake, but for commercial reasons. Never before…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Geoff Short · Apollo 11Blue OriginBuzz AldrinElon Musk
Share
Fifty Years Later, The Space Race is Back On

Key takeaways

01

In the time since Neil Armstrong and Buzz Aldrin first landed on the moon on July 20, 1969, only 10 other men have walked on the lunar surface.

02

Fifty years after this marvel of human achievement, there is a new desire to go back, not simply for exploration’s sake, but for commercial reasons.

In the time since Neil Armstrong and Buzz Aldrin first landed on the moon on July 20, 1969, only 10 other men have walked on the lunar surface. Fifty years after this marvel of human achievement, there is a new desire to go back, not simply for exploration’s sake, but for commercial reasons.

Never before have there been as many space-oriented startups as there are today, and public-private relationships are developing quickly across the United States.

The Public-Private Push

The Trump administration has laid out a plan to return to the moon by 2024 with the goal to have a sustained presence by 2028, and entrepreneurs are racing climb aboard. Whether this is a realistic goal remains to be seen.

Billionaires Elon Musk and Jeff Bezos have publicly led the movement with their companies SpaceX and Blue Origin, respectively. Entrepreneurs from across the globe, and the venture capitalists backing them see an opportunity for tourism among the stars, resource mining, and a potential launching pad to planets including Mars.

For the first time since the 1960s, a genuine space race is officially heating up.

According to the Wall Street Journal, 90 percent of the $8.4 billion that has been spent by venture capitalists on space startups has been done in the past five years alone.

The Uncertain Horizon

Still, questions remain about the return on investment of the moon. With uncertainty about the timeline and ultimate plans, some investors remain leery.

The U.S. government however, seeing China and Russia gear up for trips to the moon, has little choice but to hand out contracts to private companies intent on getting there quickly.

Startups with application in everything from defense to hospitality are vying for access to the moon and Mars, and competition is accelerating the process of a return to the lunar surface.

For more on the space race head to our science page!

Make sure to follow us on Twitter at @ScienceMKSL.

About the author

GS
Geoff Short

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

GS
Geoff Short